Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Definium Therapeutics reported positive topline results from the Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder, meeting the primary endpoint of change in HAM-A score at Week 12. Participants receiving DT120 ODT achieved a placebo-adjusted reduction of 5.4 points compared to placebo (p<0.0001), with a Cohen's d effect size of 0.81, and the drug was generally well tolerated with no new safety signals.
Key figures
- Drug Name
- DT120 (lysergide)
- Phase Of Trial
- Phase 3
- P value
- <0.0001
- Cohens d
- 0.81
- Ham a change dt120
- -11.6
- Response rate dt120
- 43%
- Ham a change placebo
- -6.2
- Remission rate dt120
- 14%
- Response rate placebo
- 16%
- Remission rate placebo
- 4%
- Ham a placebo adjusted difference
- -5.4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.